An observational study in Taurolidine Lock Solution, sponsored by University Hospital, Grenoble. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by University Hospital, Grenoble · Observational
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.
This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
112 studies on the registry are indexed under Catheter-Related Infections; 18 are open to participants now.
This study's planned enrollment of 45 is below the median of 175 across 22 observational studies indexed under Catheter-Related Infections.
Browse Catheter-Related Infections studies →University Hospital, Grenoble is the lead sponsor of 837 studies on the registry; 207 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients meeting the inclusion criteria will be recruited consecutively over a three-month period to minimize the risk of selection bias.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.
Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product). Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion. Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use). Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit
Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions.
Quantify, using a self-assigned score, nurses' level of knowledge concerning taurolidine lock solutions. Proportion of nurses aware of the various properties of lock solutions according to the references available on the market.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation.
Nature and number of service providers working with patients at home.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the supply chain for taurolidine lock solutions.
Nature and proportions of procurement methods for taurolidine lock solutions for patients at home.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the elements related to PICC placement.
Nature and proportions of elements related to PICC placement: number of lumens, vein of insertion, side of insertion, duration of placement, and role of the inserter (nurse anesthetists or physician).
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the functional status of the PICC over time.
Proportion of PICC in place and functional at 8 and 30 days post-insertion, defined as not requiring premature removal and allowing infusion and blood sampling.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe complications related to PICC placement.
Nature and proportions of complications related to the PICC occurring within 8 and 30 days post-insertion.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the causes of premature PICC removal.
Nature and proportions of causes for premature PICC-line removal within 8 and 30 days post-insertion.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe adverse events related to the use of taurolidine lock solutions.
Nature and proportion of adverse events potentially related to the use of a taurolidine lock solution, as reported by patients or healthcare providers.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions.
Nature and proportion of difficulties encountered by home-care nurses when using taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the information sources used by healthcare professionals regarding taurolidine lock solutions.
Nature and proportion of information sources consulted by nurses in the event of problems related to the use of a taurolidine lock solution or to the use of the PICC.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions.
Proportion of nurses who would report to device vigilance any adverse events related to the use of a taurolidine lock solution or to the use of the PICC, should such events occur.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Mar 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →